This was always a potential concern, even back when I was frequently prescribing them
Yet, amid the promising outcomes, a growing number of patients find themselves grappling with a new and complex challenge: What happens next
In a subset of mice, GLP-1R antagonist (exendin-3, Tocris) was administered intraperitoneally before oral glucose challenge
It has been proven that glucagon-like peptide-1 receptor (GLP-1R) agonists control blood glucose concentrations through a multitude of mechanisms, such as increased satiety, slow stomach emptying, decreased glucagon secretion, and increased insulin synthesis/secretion
For additional support, clinicians may refer patients to diabetes education programs or nutrition counseling services